Sergio Abrignani is an Italian immunologist and professor of Immunology and Immunopathology at the University of Milan. After earning his medical degree from the University of Padova, he began his international research career at the Ciba Research Center in Basel (1987–1993) and later led the Department of Immunology and Virology at Chiron Vaccines in Siena (1993–1999). From 1999 to 2005, he served as Vice President of R&D for Immunotherapy and Infectious Diseases at Chiron Corporation in San Francisco.

Since 2006 he is the Founding Director of the National Institute of Molecular Genetics (INGM) “Romeo and Enrica Invernizzi” in Milan, focusing on OMICS research and immune mechanisms in infectious and cancer diseases. He received an ERC Advanced Grant in 2011. His honors include the Gold Medal for Public Health Merit (2004) and the title of Commander of the Italian Republic (2022) for his role in managing the COVID-19 emergency.

Abrignani also founded two startups: CheckmAb (2018), developing monoclonal antibodies for cancer, and T-One Therapeutics (2022), targeting immune suppression in tumors. He serves on various scientific boards and biotech company boards, contributing actively to both research and innovation in life sciences.

Prof. Dr. Med. Sergio Abrignani